Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Improving antibody drug development using bionanotechnology

Current Opinion in Biotechnology(2021)10.1016/j.copbio.2021.10.027Source: DataRank Database

Improving antibody drug development using bionanotechnology is a research paper published in Current Opinion in Biotechnology (2021). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 0.89)OA: greenTopics (39)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

John S. Schardt ORCID,Peter M. Tessier ORCID,Emily K. Makowski ORCID

Live enrichment

PubMed:34890875 PMC:PMC9356538 OpenAlex:https://openalex.org/W4200009136

National Science Foundation

Grant: 1605266

National Science Foundation

Grant: 1804313

Collaborative Research: GOALI: Nanoparticle analysis of antibody colloidal interactions and their influence on viscoelastic properties of concentrated antibody solutions

National Science Foundation

Grant: CBET 1813963

National Institutes of Health

Grant: 1T32GM140223-01

Interdepartmental Training in Pharmacological Sciences

National Institutes of Health

Grant: F32GM137513

National Institutes of Health

Grant: R01AG050598

National Institutes of Health

Grant: R01GM104130

NIGMS NIH HHS

Grant: R35 GM136300

NIGMS NIH HHS

Grant: T32 GM140223

NIA NIH HHS

Grant: RF1 AG059723

FWCI

0.89

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9356538

publisherhttps://api.elsevier.com/content/article/PII:S0958166921002147?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0958166921002147?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.copbio.2021.10.027

Fields of Study

Monoclonal and Polyclonal Antibodies ResearchProtein purification and stabilityGlycosylation and Glycoproteins Research0301 basic medicine0303 health sciences03 medical and health sciencesAntibodies, MonoclonalDrug DevelopmentHumansMembrane ProteinsSolubilityViscosity

MeSH Terms

Drug DevelopmentAntibodies, MonoclonalHumansMembrane ProteinsSolubilityViscosity

Keywords

Drug discoveryMonoclonal antibodyAntibodyDrugDrug developmentComputational biologyIn vivoNanobiotechnologyChemistryNanotechnologyBiologyPharmacologyImmunologyBiochemistryMaterials scienceBiotechnologySolubilityViscosityAntibodies, MonoclonalHumansMembrane Proteins

Sustainable Development Goals

SDG 3: 3. Good health